The Baker Brothers added shares and are now up to 4.5% of outstanding shares
You sure don't know much about the acquisition of Enobia or how it came about based on your comments. If sure looks like you need someone to "help" you with valuation metrics of ALXN as you sure must be new to the company and/or the rare orphan drug space. As far as the DB analyst please hold your praise---she did a nice job on her conference call & was well prepared, answering all the questions well. She also raised her target after the stock was $ 160 after she finished her out years analysis.
She had a good year being one of the bull leaders in a hot sector, being out there loud & regularly. She'll get a nice bonus I'm sure.
ALXN didn't go up in size & volume on generalist or retail buying---that's for sure. It's too bad you couldn't take a meeting with the CEO & he could possibly educate you on the company dynamics----he's a doctor too !!!
no problem being in the minority???? Must be major road kill by now.....must be down about 50% over the last month or so. You must be missing SOMETHING.....!
I wonder who is buying this up --- don't you ???? I wonder ..... what do they know that you don't know ? Is it just the mo-buy the new high list crowd ??? OR did you miss something else ??? let me check with Adam Feuerstein......maybe he knows !!
Fidelity must be the dumbest bunch of rocks out there---as they have nearly 20,000,000 shares & last time I checked were not dumping a share. It appears that you are an outlier who has not closely reviewed ALXN & their current product portfolio. I am curious to hear your take on why this one has been one of the top all-time performing biotech companies if they are an absolute house-of-cards "fooling" the markets.
Roche did make an offer for ILMN but it was voted down by shareholders---as Roche was they were too cheap to make a reasonable premium to get the deal done. As far as ALXN --- Roche never made an offer. That rumor came out of the London Daily Mail & was reported in the media. Must have been a slow news day. Roche would have never paid an appropriate premium for this unique rare orphan drug company.
what airline skid ? down 1.5 points is a skid ??? AAL has been a rocket & is due for a modest pause.
that was rumortrage BS planted in the London Daily Mail by hedges. For those familiar with Roche knows that they never pay a premium for anything---let alone a company in the rare orphan drug space which would command a healthy premium.
Roche could buy almost any company but they're too cheap & think they can do it on their own.
Capital Research filed their ALXN 13G showing that they increased their position to 23,7+ MILLION shares. No pipeline ???? You better go play in another sand box as you clearly are either a novice investor or lazy.
Are you using P/Es ??? what are you comparing ALXN to ????
Sounds like you are trying to catch lightening in a bottle !!! Good luck with that.
There are some things going on behind the curtain that will keep the news flow positive so I wouldn't recommend getting too greedy. There is still pretty serious accumulation going on for those who were underweight ALXN in the sector. Unless you're forecasting a major market correction ALXN in my opinion will continue outperforming. There are about a dozen potential triggers in 2014 which will keep ALXN strong. But I may be too close to the story.....
Looks like you are on the wrong side of this one !! Maybe not as close to the story as maybe you should be.
nice to se the hall monitor is back ! luckily no abuse has to be spewed----posters beware ! do not post anything remotely negative or you will be vilified !
You are reaching. The stock is up over 40% YEAR TO DATE----outperforming 99+% of all stocks HANDILY over the first FIVE weeks of the year----did you by chance miss that ??????? One would throw out that the stock needs a rest to consolidate the gains. Also, oil prices have lifted a bit which may have tempered new money coming in. As far as buyers institutions are providing a strong bid for shares --- as many were unable to participate in the old bankrupt security.
The stock will be $40-45+ sometime in the second half of 2014----providing an attractive rate of return from current levels. Oh yeh......the stock is not down more than.....a point ????
You clearly aren't up to speed why institutions are buying aggressively as new data has been brought to the equation. It's somewhat difficult to find a company anywhere compounding earnings & revenue 35-40% + annually. You can't find too many investors willing to give up their shares----especially when one gets intimate with the current ALXN outlook. That is probably why little people don't own this stock & think they're smarter than everyone else.
ALXN is in excellent shape & the stock should nicely outperform the market averages & its peers this year---how's that ? I would recommend that one look at the age of the selling directors----many of which have been around since inception. The insiders know that the product plate is fuller than it has ever been in the company's history. I would recommend not getting spooked out of the company unless one is a short-term trader & needs to book profits. But remember---there are numerous reasons why institutions are buying heavily right here & the stock is on the New High List. Smart people usually don't recommend selling strength. Also, the institutions know ALL ABOUT every share that has been sold by older board members & are not troubled by it.